OpGen is a precision medicine company engaged in molecular diagnostics and informatics. Along with its subsidiaries, Curetis GmbH and Ares Genetics GmbH, Co. is developing and commercializing molecular microbiology solutions helping to guide clinicians with actionable information about life threatening infections. Co.'s existing product portfolio includes Unyvero, Acuitas Antimicrobial Resistance (AMR) Gene Panel, and the ARES Technology Platform including ARES reference database on antimicrobial resistance, Next Generation Sequencing technology and Artificial Intelligence-powered bioinformatics solutions for AMR surveillance, outbreak analysis, and antibiotic response prediction. We show 28 historical shares outstanding datapoints in our coverage of OPGN's shares outstanding history.
Understanding the changing numbers of OPGN shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like OPGN versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching OPGN by allowing them to research OPGN shares outstanding history
as well as any other stock in our coverage universe. |
Free OPGN Email Alerts:
Video: Shares Outstanding Importance
